These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 10996837)
1. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Ifthikharuddin JJ; Mieles LA; Rosenblatt JD; Ryan CK; Sahasrabudhe DM Am J Hematol; 2000 Oct; 65(2):171-3. PubMed ID: 10996837 [TBL] [Abstract][Full Text] [Related]
2. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases]. Chen DB; Wang Y; Song QJ; Shen DH Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829 [TBL] [Abstract][Full Text] [Related]
3. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. Zompi S; Tulliez M; Conti F; Leblond V; Gaulard P; Blanche P; Durand F; Ghandi D; Dreyfus F; Louvel A; Calmus Y; Bouscary D J Hepatol; 2000 Mar; 32(3):521-7. PubMed ID: 10735625 [TBL] [Abstract][Full Text] [Related]
4. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791 [TBL] [Abstract][Full Text] [Related]
5. [Post-transplantation lymphoproliferative disorder in childhood]. Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879 [TBL] [Abstract][Full Text] [Related]
6. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Oertel SH; Anagnostopoulos I; Bechstein WO; Liehr H; Riess HB Transplantation; 2000 Feb; 69(3):430-2. PubMed ID: 10706055 [TBL] [Abstract][Full Text] [Related]
7. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Svoboda J; Kotloff R; Tsai DE Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab. Maldonado NI; Cabanillas F; Jaffe ES; Raffeld M; Lozada L J Clin Oncol; 2011 Aug; 29(22):e658-60. PubMed ID: 21646613 [No Abstract] [Full Text] [Related]
9. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845 [TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091 [TBL] [Abstract][Full Text] [Related]
11. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Oertel SH; Verschuuren E; Reinke P; Zeidler K; Papp-Váry M; Babel N; Trappe RU; Jonas S; Hummel M; Anagnostopoulos I; Dörken B; Riess HB Am J Transplant; 2005 Dec; 5(12):2901-6. PubMed ID: 16303003 [TBL] [Abstract][Full Text] [Related]
12. Rituximab treatment for posttransplantation lymphoproliferative disorder after small bowel transplantation. Nishida S; Kato T; Burney T; Levi D; Nery J; Madariaga J; Mittal N; Weppler D; Ruiz P; Tzakis A Transplant Proc; 2002 May; 34(3):957. PubMed ID: 12034259 [No Abstract] [Full Text] [Related]
13. [Post-transplant lymphoproliferative disorders: a report of two cases]. Wang ZM; Wang LJ; Yu XR; Xu LM Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):639-40. PubMed ID: 17134580 [No Abstract] [Full Text] [Related]
14. Rituximab in the treatment of pediatric small bowel transplant patients with posttransplant lymphoproliferative disorder unresponsive to standard treatment. McGhee W; Mazariegos GV; Sindhi R; Abu-Elmagd K; Reyes J Transplant Proc; 2002 May; 34(3):955-6. PubMed ID: 12034258 [No Abstract] [Full Text] [Related]
15. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation. Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216 [TBL] [Abstract][Full Text] [Related]
16. Post-transplant lymphoproliferative disorder treated with rituximab: case report. Meng HT; Li Y; Liu JH; Xu GX; Teng XD Chin Med J (Engl); 2007 May; 120(9):841-3. PubMed ID: 17531130 [No Abstract] [Full Text] [Related]
17. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ; Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060 [TBL] [Abstract][Full Text] [Related]